EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Prevention of bicalutamide-induced breast events in patients with prostate cancer: a meta-analysis of randomized controlled trials

Luca Spagnolo, Daniele Tienforti, Carolina Moretto, Camilla Tonni, Vittoria Donatelli, Alessandro Ferranti, Gennaro Puocci, Claudio Capuano, Arcangelo Barbonetti

Journal of Endocrinological Investigation · 17.04.2025 · 48 (7) · 1659-1668

DOI: 10.1007/s40618-025-02583-8 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Endocrinological Investigation, online erschienen am 17.04.2025. Verfasst von Luca Spagnolo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Andrology Unit, Department of Clinical Medicine, Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy. Hauptthemen laut MEDLINE: Anilides, Tosyl Compounds, Nitriles, Prostatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi dell’Aquila.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aimed to quantitatively assess the effectiveness of tamoxifen, anastrozole, and radiotherapy in preventing bicalutamide-induced breast events—specifically gynecomastia and breast pain—in patients with prostate cancer.

Methods

A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted according to PRISMA-P guidelines. A comprehensive search was performed in PubMed, Scopus, and Web of Science for English-language studies without temporal restrictions. Studies were included if they involved prostate cancer patients treated with bicalutamide receiving preventive interventions (tamoxifen, anastrozole, or radiotherapy) compared to bicalutamide alone (or bicalutamide plus placebo/sham). Data extraction focused on the incidence of gynecomastia and breast pain, and study quality was assessed using the Jadad scale. Risk ratios (RR) with 95% confidence intervals (CI) were calculated using fixed- or random-effects models, and heterogeneity was evaluated with the I² statistic. Publication bias was explored via funnel plots and the trim-and-fill method.

Results

Nine RCTs met the inclusion criteria. Tamoxifen significantly reduced the risk of breast events by 82% (RR: 0.18, 95% CI: 0.08–0.38 for gynecomastia and RR: 0.18, 95% CI: 0.07–0.43 for breast pain). Radiotherapy reduced gynecomastia risk by 52% (RR: 0.48, 95% CI: 0.38–0.59) and breast pain by 34% (RR: 0.66, 95% CI: 0.48–0.90). Anastrozole did not show significant benefit.

Conclusion

Tamoxifen appears to be the most effective strategy for preventing bicalutamide-induced breast events, with radiotherapy serving as a viable alternative, and anastrozole offering no benefit. Further large-scale, high-quality studies are needed to confirm these findings and refine preventive treatment recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnilidesTosyl CompoundsNitrilesProstatic NeoplasmsGynecomastiaMastodyniaHumansMaleRandomized Controlled Trials as TopicAndrogen AntagonistsTamoxifen

Stichwörter der Autor:innen

AromataseBicalutamideGynecomastiaRadiotherapyTamoxifenTestosterone

Substanzen

bicalutamideAnilidesTosyl CompoundsNitrilesAndrogen AntagonistsTamoxifen

Autor:innen und Institutionen

  • Andrology Unit, Department of Clinical Medicine, Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
  • Andrology Unit, Department of Clinical Medicine, Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy. danieletienforti@gmail.com.
  • Spinal Unit, San Raffaele Sulmona Institute, Sulmona, Italy. danieletienforti@gmail.com.
  • Department of Clinical Medicine, Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, 67100, Italy. danieletienforti@gmail.com.
  • Department of Veterinary Medicine, University of Teramo, Teramo, Italy.

Förderung

  • Università degli Studi dell’Aquila

Zitieren

APA

Spagnolo, L., Tienforti, D., Moretto, C., Tonni, C., Donatelli, V., Ferranti, A., Puocci, G., Capuano, C., & Barbonetti, A. (2025). Prevention of bicalutamide-induced breast events in patients with prostate cancer: a meta-analysis of randomized controlled trials. Journal of Endocrinological Investigation, 48(7), 1659-1668. https://doi.org/10.1007/s40618-025-02583-8

Vancouver

Spagnolo L, Tienforti D, Moretto C, Tonni C, Donatelli V, Ferranti A, et al. Prevention of bicalutamide-induced breast events in patients with prostate cancer: a meta-analysis of randomized controlled trials. Journal of Endocrinological Investigation. 2025;48(7):1659-1668. doi:10.1007/s40618-025-02583-8

BibTeX
@article{Spagnolo2025,
  author = {Spagnolo, Luca and Tienforti, Daniele and Moretto, Carolina and Tonni, Camilla and Donatelli, Vittoria and Ferranti, Alessandro and Puocci, Gennaro and Capuano, Claudio and Barbonetti, Arcangelo},
  title = {Prevention of bicalutamide-induced breast events in patients with prostate cancer: a meta-analysis of randomized controlled trials},
  journal = {Journal of Endocrinological Investigation},
  year = {2025},
  volume = {48},
  number = {7},
  pages = {1659--1668},
  doi = {10.1007/s40618-025-02583-8}
}
Kostenlos starten →